Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Chronic Phase

NCT03883087 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT03883087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03883087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-center, Open Label Study of HQP1351 in Chinese Patients of Chronic Myeloid Leukemia With T315I Mutation in Chronic Phase
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
April 8, 2019
Completion date
February 28, 2025
Enrollment
41 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase